Over-expression of ST3Gal-I promotes mammary tumorigenesis

Gianfranco Picco; Sylvain Julien; Inka Brockhausen; Richard Beatson; Aristotelis Antonopoulos; Stuart Haslam; Ulla Mandel; Anne Dell; Sarah Pinder; Joyce Taylor-Papadimitriou; Joy Burchell

doi:10.1093/glycob/cwq085

Over-expression of ST3Gal-I promotes mammary tumorigenesis

Gianfranco Picco, Sylvain Julien, Inka Brockhausen, Richard Beatson, Aristotelis Antonopoulos, Stuart Haslam, Ulla Mandel, Anne Dell, Sarah Pinder, Joyce Taylor-Papadimitriou, Joy Burchell

Research output: Contribution to journal › Article › peer-review

116 Citations (Scopus)

Abstract

Changes in glycosylation are common in malignancy, and as almost all surface proteins are glycosylated, this can dramatically affect the behavior of tumor cells. In breast carcinomas, the O-linked glycans are frequently truncated, often as a result of premature sialylation. The sialyltransferase ST3Gal-I adds sialic acid to the galactose residue of core 1 (Gal beta 1,3GalNAc) O-glycans and this enzyme is over-expressed in breast cancer resulting in the expression of sialylated core 1 glycans. In order to study the role of ST3Gal-I in mammary tumor development, we developed transgenic mice that over-express the sialyltransferase under the control of the human membrane-bound mucin 1 promoter. These mice were then crossed with PyMT mice that spontaneously develop mammary tumors. As expected, ST3Gal-I transgenic mice showed increased activity and expression of the enzyme in the pregnant and lactating mammary glands, the stomach, lungs and intestine. Although no obvious defects were observed in the fully developed mammary gland, when these mice were crossed with PyMT mice, a highly significant decrease in tumor latency was observed compared to the PyMT mice on an identical background. These results indicate that ST3Gal-I is acting as a tumor promoter in this model of breast cancer. This, we believe, is the first demonstration that over-expression of a glycosyltransferase involved in mucin-type O-linked glycosylation can promote tumorigenesis.

Original language	English
Pages (from-to)	1241 - 1250
Number of pages	10
Journal	Glycobiology
Volume	20
Issue number	10
DOIs	https://doi.org/10.1093/glycob/cwq085
Publication status	Published - Oct 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/glycob/cwq085

Cite this

@article{5f70aa34155d43a4a4fe8d20d73d8374,

title = "Over-expression of ST3Gal-I promotes mammary tumorigenesis",

abstract = "Changes in glycosylation are common in malignancy, and as almost all surface proteins are glycosylated, this can dramatically affect the behavior of tumor cells. In breast carcinomas, the O-linked glycans are frequently truncated, often as a result of premature sialylation. The sialyltransferase ST3Gal-I adds sialic acid to the galactose residue of core 1 (Gal beta 1,3GalNAc) O-glycans and this enzyme is over-expressed in breast cancer resulting in the expression of sialylated core 1 glycans. In order to study the role of ST3Gal-I in mammary tumor development, we developed transgenic mice that over-express the sialyltransferase under the control of the human membrane-bound mucin 1 promoter. These mice were then crossed with PyMT mice that spontaneously develop mammary tumors. As expected, ST3Gal-I transgenic mice showed increased activity and expression of the enzyme in the pregnant and lactating mammary glands, the stomach, lungs and intestine. Although no obvious defects were observed in the fully developed mammary gland, when these mice were crossed with PyMT mice, a highly significant decrease in tumor latency was observed compared to the PyMT mice on an identical background. These results indicate that ST3Gal-I is acting as a tumor promoter in this model of breast cancer. This, we believe, is the first demonstration that over-expression of a glycosyltransferase involved in mucin-type O-linked glycosylation can promote tumorigenesis.",

author = "Gianfranco Picco and Sylvain Julien and Inka Brockhausen and Richard Beatson and Aristotelis Antonopoulos and Stuart Haslam and Ulla Mandel and Anne Dell and Sarah Pinder and Joyce Taylor-Papadimitriou and Joy Burchell",

year = "2010",

month = oct,

doi = "10.1093/glycob/cwq085",

language = "English",

volume = "20",

pages = "1241 -- 1250",

journal = "Glycobiology",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Over-expression of ST3Gal-I promotes mammary tumorigenesis

AU - Picco, Gianfranco

AU - Julien, Sylvain

AU - Brockhausen, Inka

AU - Beatson, Richard

AU - Antonopoulos, Aristotelis

AU - Haslam, Stuart

AU - Mandel, Ulla

AU - Dell, Anne

AU - Pinder, Sarah

AU - Taylor-Papadimitriou, Joyce

AU - Burchell, Joy

PY - 2010/10

Y1 - 2010/10

N2 - Changes in glycosylation are common in malignancy, and as almost all surface proteins are glycosylated, this can dramatically affect the behavior of tumor cells. In breast carcinomas, the O-linked glycans are frequently truncated, often as a result of premature sialylation. The sialyltransferase ST3Gal-I adds sialic acid to the galactose residue of core 1 (Gal beta 1,3GalNAc) O-glycans and this enzyme is over-expressed in breast cancer resulting in the expression of sialylated core 1 glycans. In order to study the role of ST3Gal-I in mammary tumor development, we developed transgenic mice that over-express the sialyltransferase under the control of the human membrane-bound mucin 1 promoter. These mice were then crossed with PyMT mice that spontaneously develop mammary tumors. As expected, ST3Gal-I transgenic mice showed increased activity and expression of the enzyme in the pregnant and lactating mammary glands, the stomach, lungs and intestine. Although no obvious defects were observed in the fully developed mammary gland, when these mice were crossed with PyMT mice, a highly significant decrease in tumor latency was observed compared to the PyMT mice on an identical background. These results indicate that ST3Gal-I is acting as a tumor promoter in this model of breast cancer. This, we believe, is the first demonstration that over-expression of a glycosyltransferase involved in mucin-type O-linked glycosylation can promote tumorigenesis.

AB - Changes in glycosylation are common in malignancy, and as almost all surface proteins are glycosylated, this can dramatically affect the behavior of tumor cells. In breast carcinomas, the O-linked glycans are frequently truncated, often as a result of premature sialylation. The sialyltransferase ST3Gal-I adds sialic acid to the galactose residue of core 1 (Gal beta 1,3GalNAc) O-glycans and this enzyme is over-expressed in breast cancer resulting in the expression of sialylated core 1 glycans. In order to study the role of ST3Gal-I in mammary tumor development, we developed transgenic mice that over-express the sialyltransferase under the control of the human membrane-bound mucin 1 promoter. These mice were then crossed with PyMT mice that spontaneously develop mammary tumors. As expected, ST3Gal-I transgenic mice showed increased activity and expression of the enzyme in the pregnant and lactating mammary glands, the stomach, lungs and intestine. Although no obvious defects were observed in the fully developed mammary gland, when these mice were crossed with PyMT mice, a highly significant decrease in tumor latency was observed compared to the PyMT mice on an identical background. These results indicate that ST3Gal-I is acting as a tumor promoter in this model of breast cancer. This, we believe, is the first demonstration that over-expression of a glycosyltransferase involved in mucin-type O-linked glycosylation can promote tumorigenesis.

U2 - 10.1093/glycob/cwq085

DO - 10.1093/glycob/cwq085

M3 - Article

C2 - 20534593

VL - 20

SP - 1241

EP - 1250

JO - Glycobiology

JF - Glycobiology

IS - 10

ER -

Over-expression of ST3Gal-I promotes mammary tumorigenesis

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this